Machine Learning Analysis of Two-photon Fluorescence Microscopy of Dermatologic Biopsies
Machine Learning Analysis of Expanded Two-photon Imaging of Skin Biopsy Specimens
The goal of this study is to investigate the ability of a machine learning model to evaluate two-photon fluorescence microscopy images of dermatologic biopsies at point of care.
The main question it aims to answer is:
• How well do two-photon fluorescence images of biopsies taken in a clinic and evaluated by a machine learning model agree with conventional histology?
調査の概要
詳細な説明
This study will image biopsy specimens at point of care using two-photon fluorescence microscopy (TPFM) and then assess how well the images predict the eventual clinical diagnosis using a machine learning model. Because two-photon images can be acquired from small biopsy specimens within minutes of excision, they could potentially be used to immediately diagnose patients, but the accuracy of TPFM for various skin conditions is unknown.
Individual biopsy specimens in a dermatology clinic will be imaged using TPFM shortly after biopsy procedures. Immediately following imaging, a machine learning model will evaluate the TPFM images then compute a confidence score for a diagnosis of basal cell carcinoma (BCC), squamous cell carcinoma, and non-cancer. The relative confidence in each diagnosis will be compared, and if sufficient confidence is achieved, the model will render a diagnosis or else flag the specimen as indeterminate for manual pathologist review. This workflow will evaluate the use of ML + TPFM to perform point of care diagnosis of skin lesions.
Following TPFM imaging, the specimen will be submitted for histological processing, which will guide actual patient treatment. Following conclusion of patient treatment, the resulting histology slides will be scanned for comparison and the final patient diagnosis recorded. Images of the histology slides will be read by a pathologist to establish a gold-standard diagnosis. The official diagnosis and the diagnosis from the collaborating pathologist will be compared.
Patient treatment will still be decided by conventional histopathology. TPFM will not be used to change treatment.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Michael Giacomelli, Ph.D
- 電話番号：5852766260
- メール：mgiacome@ur.rochester.edu
研究場所
-
-
New York
-
Victor、New York、アメリカ、14654
- 募集
- Rochester Dermatologic Surgery
-
コンタクト：
- Sherrif Ibrahim, M.D.-Ph.D.
- 電話番号：585-222-1400
- メール：dr.ibrahim@rochesterdermsurgery.com
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Punch, excisional or shave biopsy specimen
Exclusion Criteria:
- Biopsy indication includes melanoma or dysplastic/atypical nevus
- Excision thickness of less than 1 mm
- Excision longest dimension less than 2 mm
- Excision performed as multiple pieces in a single specimen container
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：診断
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：TPFM imaging of biopsy
Specimens will be imaged with TPFM and diagnosed using a machine learning model
|
Ex vivo tissues will be imaged with two-photon microscopy and analyzed with machine learning for diagnosis
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Sensitivity of Machine Learning Analysis of Two Photon Fluorescence Microscopy Images At Point of Care
時間枠：During or immediately following patient biopsy (same day)
|
A machine learning model will evaluate TPFM images of patient biopsies at point of care.
Sensitivity will be calculated for the machine learning model using two photon fluorescence microscopy images.
Sensitivity is defined as the number of true positive diagnoses divided by the sum of true positive and false negative diagnoses among biopsy specimens for which the machine learning model provides a definitive diagnosis.
The patient's ultimate clinical diagnosis will serve as the reference standard.
|
During or immediately following patient biopsy (same day)
|
|
Specificity of Machine Learning Analysis of Two Photon Fluorescence Microscopy Images At Point of Care
時間枠：During or immediately following patient biopsy (same day)
|
A machine learning model will evaluate TPFM images of patient biopsies at point of care.
Specificity will be calculated for the machine learning model using two photon fluorescence microscopy images.
Specificity is defined as the number of true negative diagnoses divided by the sum of true negative and false positive diagnoses among biopsy specimens for which the machine learning model provides a definitive diagnosis.
The patient's ultimate clinical diagnosis will serve as the reference standard.
|
During or immediately following patient biopsy (same day)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Discordant Diagnoses Attributable to Machine Learning Model Interpretation Errors
時間枠：After completion of patient diagnosis (typically 1-2 weeks after procedure)
|
For biopsy specimens with discordant diagnoses between the machine learning model and the patient's ultimate clinical diagnosis, a dermatopathologist will review each case and classify the source of disagreement as machine learning model interpretation error, image quality limitation, or image coregistration error.
The proportion of discordant diagnoses attributable to each source of disagreement will be reported.
|
After completion of patient diagnosis (typically 1-2 weeks after procedure)
|
|
Proportion of Biopsy Specimens With a Definitive Machine Learning Diagnosis
時間枠：During or immediately following patient biopsy (same day)
|
The proportion of biopsy specimens for which the machine learning model provides a definitive diagnosis based on two photon fluorescence microscopy images will be calculated as the number of specimens receiving a definitive diagnosis divided by the total number of specimens evaluated.
|
During or immediately following patient biopsy (same day)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- STUDY00009823B
- R37CA258376 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。